Rohto Pharmaceutical Co.,Ltd.
Simbol: 4527.T
JPX
3200
JPYTržna cena danes
23.2296
Razmerje P/E
0.8870
Razmerje PEG
730.04B
Kapaciteta MRK
- 0.01%
Donos DIV
Rohto Pharmaceutical Co.,Ltd. (4527-T) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 79951 | 72791 | 52964 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 1008 | 661 | -1199 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 60656 | 51682 | 47865 | ||||||||||||||||
balance-sheet.row.inventory | 0 | 41062 | 33527 | 27925 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 29547 | 24678 | 20975 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 190246 | 164306 | 133071 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 66182 | 62839 | 49790 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 2564 | 2954 | 4014 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 6997 | 6338 | 3521 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 9561 | 9292 | 7535 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 32629 | 27471 | 27425 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 5371 | 5297 | 4606 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 5686 | 5419 | 3361 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 119429 | 110318 | 92717 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 2 | 3 | 2 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 309677 | 274627 | 225790 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 16025 | 13660 | 9603 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 4177 | 8033 | 2312 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 6230 | 3185 | 6138 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 7516 | 13350 | 5787 | ||||||||||||||||
Deferred Revenue Non Current | 0 | 3146 | 3387 | 5126 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 29368 | 27256 | 10008 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 14439 | 19311 | 12708 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1184 | 1184 | 179 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 94601 | 90799 | 69179 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 6504 | 6504 | 6504 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 184005 | 162195 | 145511 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 18705 | 8735 | 3167 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 354 | 851 | 725 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 209568 | 178285 | 155907 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 309677 | 274627 | 225790 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 5508 | 5543 | 704 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 215076 | 183828 | 156611 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 33637 | 28132 | 26226 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 11693 | 21383 | 8099 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | -68258 | -51408 | -44865 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 34290 | 27953 | 23006 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 7801 | 7673 | 6748 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -11277 | 458 | 3402 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | -7560 | -30 | 2464 | ||||||||||||||||
cash-flows.row.inventory | 0 | -6105 | -3061 | 3188 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 1716 | 3323 | -2811 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | 672 | 226 | 561 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 110 | -8834 | -13148 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -9908 | -11328 | -10304 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -1582 | -1203 | -1516 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -5940 | -5615 | -2206 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2641 | 1963 | 4050 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 1613 | -223 | -261 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -13176 | -16406 | -10237 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | -8761 | -3133 | -1880 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | -4676 | -3422 | -2965 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | -2762 | 10025 | 2498 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -16199 | 3470 | -2347 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 5236 | 4335 | 96 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 6786 | 18651 | 7589 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 77691 | 70905 | 52254 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 70905 | 52254 | 44665 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 30924 | 27250 | 20008 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -9908 | -11328 | -10304 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 21016 | 15922 | 9704 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 238664 | 199646 | 181053 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 101243 | 83157 | 74326 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 137421 | 116489 | 106727 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | -63 | 246 | 260 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 103457 | 87135 | 83732 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 204700 | 170292 | 158058 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 962 | 368 | 341 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 247 | 248 | 145 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 751 | -240 | 1139 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -63 | 246 | 260 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 751 | -240 | 1139 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 247 | 248 | 145 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 7801 | 7673 | 6748 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | 33959 | 29349 | 22990 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 34290 | 27953 | 23006 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 7860 | 6803 | 6236 | ||||||||||||||||
income-statement-row.row.net-income | 0 | 26377 | 21127 | 16743 |
Pogosto zastavljeno vprašanje
Kaj je Rohto Pharmaceutical Co.,Ltd. (4527.T) skupna sredstva?
Rohto Pharmaceutical Co.,Ltd. (4527.T) skupna sredstva so 309677000000.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so N/A.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.582.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je 74.691.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je 0.117.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so 0.154.
Kaj je Rohto Pharmaceutical Co.,Ltd. (4527.T) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je 26377000000.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 11693000000.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 103457000000.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 0.000.